Hansa Biopharma; Expanding future potential support from gene therapy collaboration - Redeye

Hansa has established a research and development collaboration with French Genenthon based on the candidate GNT-0003 which has recently entered the pivotal study stage. If approved, some 30-40% of patients are likely to develop NABs (antibody reactions), and this is where Hansa’s Imlifidase could open up for treatment of a larger patient group. We believe this research collaboration could evolve into a commercial partnership within 12 months, depending on the preclinical (safety) outcome of the combination study and the results from the recently completed stage of the GNT-0003 study.

Länk till analysen i sin helhet: https://www.redeye.se/research/899795/hansa-biopharma-expanding-future-potential-support-from-gene-therapy-collaboration?utm_source=finwire&utm_medium=RSS